


RealRate

## PHARMACEUTICAL 2019



## Arcus Biosciences Inc. Rank 75 of 371





## PHARMACEUTICAL 2019



## Arcus Biosciences Inc. Rank 75 of 371



The relative strengths and weaknesses of Arcus Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcus Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 192% points. The greatest weakness of Arcus Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 368% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	258,948
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,935
Liabilities, Non-Current	1,792
Other Assets	4,870
Other Compr. Net Income	-65
Other Expenses	0
Other Liabilities	21,256
Other Net Income	5,265
Property and Equipment	11,107
Research and Development	49,646
Revenues	8,353
Selling, General and Administrative Expense	13,566

Output Variable	Value in 1000 USD
Assets	274,925
Liabilities	39,983
Expenses	63,212
Stockholders Equity	234,942
Net Income	-49,594
Comprehensive Net Income	-49,626
Economic Capital Ratio	36%

